IPO registrations (S-1, F-1) · Registrants
Cabaletta Bio, Inc.
- SEC CIK
- 1759138 · filings on EDGAR ↗
- Registration
- Form S-1, first filed 2019-09-30, last 2019-10-16; 1 initial registration, 1 amendment
- Outcome
- Final prospectus filed 2019-10-25; declared effective 2019-10-24
- Industry (SIC)
- Biological Products, (No Diagnostic Substances) 2836
- Incorporated in
- DE
- Business address
- 2929 ARCH STREET, SUITE 600, Philadelphia, PA 19104
- Ticker
- CABA (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Cabaletta Bio, Inc. on the corporate pages
Offering terms
- Proposed price range
- $14.00–$16.00 per share (S-1/A filed 2019-10-16)
- Final price
- $11.00 per share, below the range (424B4 filed 2019-10-25, an initial public offering)
- Shares sold
- 6,800,000
- Gross proceeds
- $74,800,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol CABA
- Lead underwriters
- Morgan Stanley; Cowen; Evercore
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: Cabaletta Bio, Inc. Fuzzy (name and state)
- Business registration: CABALETTA BIO INC Fuzzy (name and state)
- Form D issuer: Cabaletta Bio, Inc. EXACT (CIK (EXACT))
- Lobbying client: CABALETTA BIO Fuzzy (name and state)
- SEC filer: Cabaletta Bio, Inc. EXACT (CIK (EXACT))
- Person page: James E Flynn Fuzzy (officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther))
Filings 6
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2019-09-30 | S-1 | S-1 (registration) | Cabaletta Bio, Inc. | 0001193125-19-258869 ↗ |
| 2019-10-16 | S-1/A | S-1/A (amendment) | Cabaletta Bio, Inc. | 0001193125-19-268040 ↗ |
| 2019-10-24 | S-1MEF | S-1MEF (added securities) | Cabaletta Bio, Inc. | 0001193125-19-273939 ↗ |
| 2019-10-24 | EFFECT | EFFECT (declared effective) | Cabaletta Bio, Inc. | 9999999995-19-002384 ↗ |
| 2019-10-25 | 424B4 | 424B4 (final prospectus) | Cabaletta Bio, Inc. | 0001193125-19-274807 ↗ |
| 2020-11-18 | EFFECT | EFFECT (declared effective) | Cabaletta Bio, Inc. | 9999999995-20-003226 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2019-10-16 | S-1/A | registration statement | $14.00–$16.00 | 5,800,000 | - | Nasdaq CABA | 3 | primary document; range, shares headline, cover names 3 | document ↗ | |
| 2019-10-25 | 424B4 | final prospectus | $11.00 | 6,800,000 | $74,800,000 | Nasdaq CABA | 3 | primary document; price sentence, shares headline, proceeds table, cover names 3 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| 5AM Partners V, LLC | TenPercentOwner | 6 | 2019–2021 | ||
| 5AM Ventures V, L.P. | TenPercentOwner | 6 | 2019–2021 | ||
| Binder Gwendolyn | Officer | EVP, Science & Technology; President, Science & Tech.; See Remarks | 20 | 2019–2026 | |
| Bollard Catherine | Director | 10 | 2019–2026 | ||
| Chang David J. | Officer | Chief Medical Officer | 11 | 2019–2026 | |
| DANIELS BRIAN | Director | 4 | 2019–2021 | ||
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | TenPercentOwnerOther | 2 | 2019 | ||
| Deerfield Mgmt IV, L.P. | TenPercentOwnerOther | 2 | 2019 | ||
| Deerfield Mgmt L.P. | TenPercentOwnerOther | 2 | 2019 | ||
| Deerfield Private Design Fund IV, L.P. | TenPercentOwnerOther | 2 | 2019 | ||
| Deerfield Special Situations Fund, L.P. | TenPercentOwnerOther | 2 | 2019 | ||
| Flynn James E | TenPercentOwnerOther | 2 | 2019 | person page Fuzzy | |
| Green Jeremy | TenPercentOwner | 2 | 2019 | ||
| HENRIQUES RICHARD C JR | Director | 8 | 2019–2026 | ||
| Marda Anup | Officer | Chief Financial Officer | 11 | 2019–2026 | |
| Nichtberger Steven | Director,Officer | President & CEO | 17 | 2019–2026 | |
| PARMAR KUSH | TenPercentOwner | 6 | 2019–2021 | ||
| Redmile Group, LLC | TenPercentOwner | 2 | 2019 | ||
| ROCKLAGE SCOTT M | TenPercentOwner | 6 | 2019–2021 | ||
| Schwab Andrew J. | TenPercentOwner | 6 | 2019–2021 | ||
| Simon Mark | Director | 11 | 2019–2026 | ||
| Stalter John Brian | Officer | General Counsel | 3 | 2019–2021 | |
| DEERFIELD PARTNERS, L.P. | TenPercentOwnerOther | 1 | 2019 | ||
| 5AM Opportunities I (GP), LLC | TenPercentOwner | 5 | 2019–2021 | ||
| 5AM Opportunities I, L.P. | TenPercentOwner | 5 | 2019–2021 | ||
| Brun Scott C. | Director | 8 | 2021–2026 | ||
| Gerard Michael | Officer | General Counsel | 9 | 2021–2026 | |
| Das Arun | Officer | Chief Business Officer | 7 | 2022–2026 | |
| Tomasello Shawn | Director | 7 | 2023–2026 | ||
| Gavel Steve | Officer | Chief Commercial Officer; CHIEF COMMERCIAL OFFICER | 3 | 2025–2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2019-01-14 | Cabaletta Bio, Inc. | Biotechnology | Indefinite | $49,999,998 | 16 | 1 |
| 2018-12-10 | Cabaletta Bio, Inc. | Biotechnology | Indefinite | $38,255,593 | 11 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Business registration | Cabaletta Bio, Inc. | PA | State business registries | name and state |
| Business registration | CABALETTA BIO INC | PA | State business registries | name and state |
| Plan sponsor | CABALETTA BIO INC | PA | Form 5500 (employee benefit plans) | name and state |
| Form D issuer | Cabaletta Bio, Inc. | PA | Form D private offerings | CIK (EXACT) |
| Lobbying client | CABALETTA BIO | PA | Federal lobbying (LDA) | name and state |
| SEC filer | Cabaletta Bio, Inc. | SEC filers (EDGAR) | CIK (EXACT) | |
| Trademark owner | Cabaletta Bio, Inc. | PA | Trademarks (USPTO) | name and state |
| Person page | James E Flynn | People (Form 990 officers, directors and employees) | officer, director or 10% owner on the company's Forms 3, 4 and 5 (TenPercentOwnerOther) |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Biological Products, (No Diagnostic Substances), PA first:
- APOLLON INC PA
- Aevi Genomic Medicine, LLC PA
- Ocugen, Inc. PA
- Spark Therapeutics, Inc. PA
- Krystal Biotech, Inc. PA
- Passage BIO, Inc. PA
- Century Therapeutics, Inc. PA
- Aphton CORP PA
- Aceragen, Inc. PA
- GENAERA CORP PA
In other datasets, the same topic (Health) in PA:
- Nonprofit: 445 FOUNDATION (Nonprofits (IRS Form 990))
Interests: Biological Products, (No Diagnostic Substances) · Health